Barclays PLC Purchases 50,109 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Barclays PLC grew its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 29.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 218,455 shares of the biotechnology company’s stock after purchasing an additional 50,109 shares during the quarter. Barclays PLC owned approximately 0.14% of Heron Therapeutics worth $434,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Marshall Wace LLP increased its holdings in Heron Therapeutics by 256.2% during the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after buying an additional 1,266,697 shares during the last quarter. Clearline Capital LP raised its holdings in Heron Therapeutics by 48.9% in the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after purchasing an additional 731,246 shares during the period. AQR Capital Management LLC lifted its position in Heron Therapeutics by 1,460.9% during the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock valued at $2,125,000 after purchasing an additional 568,238 shares in the last quarter. Congress Park Capital LLC grew its holdings in Heron Therapeutics by 25.3% during the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock valued at $3,936,000 after purchasing an additional 399,577 shares during the period. Finally, Squarepoint Ops LLC increased its position in Heron Therapeutics by 369.0% in the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock worth $1,273,000 after buying an additional 286,160 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

HRTX opened at $1.66 on Friday. The stock has a market capitalization of $252.48 million, a price-to-earnings ratio of -9.22 and a beta of 1.60. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The company has a fifty day moving average of $1.51 and a 200 day moving average of $2.07.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $32.81 million during the quarter, compared to the consensus estimate of $36.40 million. During the same period last year, the firm posted ($0.17) earnings per share. On average, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on HRTX shares. StockNews.com downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.